Revna Biosciences
PrivateLast Round
Growth Equity
Mar 1, 2026
Total Funding Raised
$118,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Revna Biosciences operates in Healthcare & Life Sciences and is based in Accra. Its latest recorded funding round was a Growth Equity round in March 2026.
Revna Biosciences is a biotechnology company that provides precision medicine services, advanced molecular diagnostics, and biobanking infrastructure in Africa.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revna Biosciences Comparables
Compare Revna Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Yemaachi Biotechnology | 84% | |
| Pahtia Technologies | 63% | |
| Roche Holding | 63% |
For institutional investors. Book with your work email.
Revna Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Mar 1, 2026 | ||||
| VC Round | Dec 1, 2024 | ||||
| Grant | Mar 27, 2024 | ||||
| Grant | Aug 24, 2023 | ||||
| Seed | Nov 11, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Revna Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aruwa Capital Management | VC Round |
| Jaza Rift Ventures | Seed |
| African Diaspora Network | Seed, Grant |
| develoPPP Ventures | Grant |
| Mirepa Capital | Growth Equity |
| develoPPP | Grant |
| Tekedia Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 55% MoM, reaching 1K.
- Jul 26, 2026
Added A2LA as a customer
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesAug 26, 2026
RevnaBio launches the LifeReady(TM) DNA Test, which identifies genetic markers influencing strength, endurance, and recovery, on Aug 26th '26.
For institutional investors. Book with your work email.
Revna Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Revna Biosciences's valuation, stock price, and market status.
Is Revna Biosciences a public or private company?
Revna Biosciences is a private company.
What is the current stock price of Revna Biosciences?
Revna Biosciences is a private company, so its shares have no public market price. Caplight tracks Revna Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Revna Biosciences worth (valuation)?
Valuation information for Revna Biosciences is not publicly available.
Can I buy Revna Biosciences stock?
Revna Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Revna Biosciences's last funding round?
Revna Biosciences's most recent funding round was Growth Equity on March 1, 2026.
Who are the main investors in Revna Biosciences?
Key investors in Revna Biosciences include develoPPP.
Will Revna Biosciences IPO soon?
No public IPO plans have been announced for Revna Biosciences.
How can I track Revna Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Revna Biosciences's shares on secondary markets.